Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H.

Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22.

PMID:
31011202
2.

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.

Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.

PMID:
30413523
3.

Evolutionary dynamics of the kinetochore network in eukaryotes as revealed by comparative genomics.

van Hooff JJ, Tromer E, van Wijk LM, Snel B, Kops GJ.

EMBO Rep. 2017 Sep;18(9):1559-1571. doi: 10.15252/embr.201744102. Epub 2017 Jun 22.

4.

Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.

Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA; BENEFICIAL investigators.

Eur J Heart Fail. 2011 Aug;13(8):899-908. doi: 10.1093/eurjhf/hfr067. Epub 2011 Jun 13.

5.

Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.

Hartog JW, van de Wal RM, Schalkwijk CG, Miyata T, Jaarsma W, Plokker HW, van Wijk LM, Smit AJ, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2010 Apr;12(4):397-403. doi: 10.1093/eurjhf/hfq001. Epub 2010 Feb 12.

6.

Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.

Willemsen S, Hartog JW, Hummel YM, Posma JL, van Wijk LM, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2010 Mar;12(3):294-300. doi: 10.1093/eurjhf/hfp207. Epub 2010 Jan 25.

7.

Reduced regional myocardial perfusion reserve is associated with impaired contractile performance in idiopathic dilated cardiomyopathy.

Tio RA, Slart RH, de Boer RA, van der Vleuten PA, de Jong RM, van Wijk LM, Willems T, Lubbers DD, Voors AA, van Veldhuisen DJ.

Neth Heart J. 2009 Dec;17(12):470-4.

8.

Influence of renal dysfunction on the pharmacokinetics of the selective Na+/H+ exchange inhibitor EMD 87 580 in patients with chronic heart failure.

Smilde TD, Linssen GC, Gallemann D, Kuhn T, Machnig T, Mol PG, Hillege HL, Van Wijk LM, Van Dijk RB, Van Veldhuisen DJ.

Int J Clin Pharmacol Ther. 2005 Nov;43(11):507-16.

PMID:
16300166
9.

Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: effects of ACE-inhibition with perindopril.

van den Heuvel AF, Blanksma PK, Siebelink HM, van Wijk LM, Boomsma F, Vaalburg W, Crijns HJ, van Veldhuisen DJ.

Int J Cardiovasc Imaging. 2001 Oct;17(5):353-9.

PMID:
12025949
10.

Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure.

Tjeerdsma G, van Wijk LM, Molhoek GP, Boomsma F, Haaksma J, van Veldhuisen DJ.

Cardiovasc Drugs Ther. 2001 Mar;15(2):139-45. Erratum in: Cardiovasc Drugs Ther 2002 Jan;16(1):79.

PMID:
11669407
11.

Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add-on beta-blockade.

Tjeerdsma G, Szabó BM, van Wijk LM, Brouwer J, Tio RA, Crijns HJ, van Veldhuisen DJ.

Eur J Heart Fail. 2001 Jan;3(1):33-9.

12.

Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function.

Tuininga YS, Crijns HJ, Oosterhuis B, Wiesfeld AC, van Wijk LM, Albronda F, de Bruin H, Jonkman JH, Kozma C, Lie KI.

J Cardiovasc Pharmacol. 1994 Mar;23(3):408-14.

PMID:
7515984
13.

Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation.

van Wijk LM, Crijns HJ, Kingma HJ, van Gilst WH, van Gelder IC, Wesseling H, Lie KI.

J Cardiovasc Pharmacol. 1990 Jun;15(6):884-91.

PMID:
1694910
14.

Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.

Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI.

Am J Cardiol. 1989 Dec 1;64(19):1317-21.

PMID:
2511744
15.

Electrophysiological properties of isradipine (PN200-110) in humans.

van Wijk LM, van den Toren WE, van Gelder I, Crijns HJ, Ruegg P, Lie KI.

J Cardiovasc Pharmacol. 1989 Sep;14(3):492-5.

PMID:
2476631
16.

Cardiac electrophysiologic properties of intravenous isradipine in patients with sick sinus syndrome.

van Wijk LM, van Gelder I, Crijns HJ, van den Toren EW, Lie KI, Rüegg PC.

Am J Med. 1989 Apr 17;86(4A):88-90.

PMID:
2523662
17.

Flecainide acetate in the treatment of supraventricular tachycardias: value of programmed electrical stimulation for long-term prognosis.

van Wijk LM, Crijns HJ, van Gilst WH, Wesseling H, Lie KI.

Am Heart J. 1989 Feb;117(2):365-9.

PMID:
2492738
18.

Effects of flecainide on the atrial defibrillation threshold.

Van Gelder IC, Crijns HJ, Van Gilst WH, De Langen CD, Van Wijk LM, Lie KI.

Am J Cardiol. 1989 Jan 1;63(1):112-4. No abstract available.

PMID:
2491771
19.

Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation.

van Wijk LM, den Heijer P, Crijns HJ, van Gilst WH, Lie KI.

J Cardiovasc Pharmacol. 1989 Jan;13(1):32-6.

PMID:
2468933
20.

Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens.

Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI.

Eur Heart J. 1988 Jun;9(6):634-8.

PMID:
3137061
21.

Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome.

Crijns HJ, den Heijer P, van Wijk LM, Lie KI.

Am Heart J. 1988 Jun;115(6):1317-21. No abstract available.

PMID:
3132032
22.

Abnormal pharmacokinetics of flecainide in a "nonresponder".

van Gelder IC, Crijns HJ, van Wijk LM, van Gilst WH, Lie KI.

Clin Cardiol. 1988 May;11(5):353-5.

23.

Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.

Dunselman PH, Kingma JH, van Wijk LM, Dijk A, Wesseling H, Lie KI.

Drugs. 1985;29 Suppl 4:58-64.

PMID:
4006780

Supplemental Content

Loading ...
Support Center